CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Hetero USA Inc.

1:17-cv-00031

Overview

Case Number 1:17-cv-00031
Filing Date 2017-01-11
Status Terminated
Termination Date 2017-03-10
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sanofi Operating Company

Represented By

2 Attorneys Listed

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Sanofi-Aventis U.S. LLC Operating Company

Represented By

2 Attorneys Listed

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Plaintiff

Aventisub LLC Operating Company

Represented By

2 Attorneys Listed

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Genzyme Corporation NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Counter Claimant

Hetero Labs Limited NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Hetero USA Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2017-01-25
1:17-cv-00070

Sanofi-Aventis U.S. LLC v. Emcure Pharmaceuticals Ltd.

U.S. Family Sibling (["US6794410"])
Status: DED
U.S. District Court 2017-01-12
1:17-cv-00040

Sanofi-Aventis U.S. LLC v. Par Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-12
1:17-cv-00039

Sanofi-Aventis U.S. LLC v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2017-01-11
1:17-cv-00034

Sanofi-Aventis U.S. LLC v. Zydus Pharmaceuticals (USA) Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00024

Sanofi-Aventis U.S. LLC v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00027

Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00019

Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00018

Sanofi-Aventis U.S. LLC v. Teva Pharmaceuticals USA, Inc.

U.S. Family Sibling (["US6794410"])
Status: DED
U.S. District Court 2017-01-03
1:17-cv-00003

Sanofi-Aventis U.S. LLC v. Biocon Limited

U.S. Family Sibling (["US6794410", "US9186346"])
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4β€²-trifluoromethylphenyl)-amide for treating multiple sclerosis
Filed: 2002-04-01
Issued: 2004-09-21
Expired (Term Ended) +1639d PTA
Expires: 2026-09-26
US9186346
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Filed: 2014-02-04
Issued: 2015-11-17
Active (7.2 yrs remaining)
Expires: 2034-02-04
US8802735
(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Filed: 2012-03-16
Issued: 2014-08-12
Active (5.3 yrs remaining)
Expires: 2032-03-16

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1639 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(16 total)
Pleading / Complaint

COMPLAINT filed against Hetero Labs Limited, Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2063000.) - filed by Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(ceg) (Entered: 01/11/2017)

Entry #1 • 2017-01-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ceg) (Entered: 01/11/2017)

Entry #2 • 2017-01-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/29/16. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/29/2019. (ceg) (Entered: 01/11/2017)

Entry #3 • 2017-01-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 B2; US 8,802,735 B2. (ceg) (Entered: 01/11/2017)

Entry #4 • 2017-01-11
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventisub LLC, Genzyme Corporation, Sanofi-Aventis U.S. LLC filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi-Aventis U.S. LLC. (Bove, Jeffrey) (Entered: 01/11/2017)

Entry #5 • 2017-01-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc